Literature DB >> 17440106

Degrasyn activates proteasomal-dependent degradation of c-Myc.

Geoffrey Bartholomeusz1, Moshe Talpaz, William Bornmann, Ling-Yuan Kong, Nicholas J Donato.   

Abstract

c-Myc is a highly unstable transcription factor whose deregulation and increased expression are associated with cancer. Degrasyn, a small synthetic molecule, induces rapid degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines. Destruction of c-Myc by degrasyn requires the presence of a region of c-Myc between amino acid residues 316 and 378 that has not previously been associated with c-Myc stability. Degrasyn-induced degradation of c-Myc depends on proteasomes but is independent of the degron regions previously shown to be important for ubiquitin-mediated targeting and proteasomal destruction of the protein. Degrasyn-dependent c-Myc proteolysis is not mediated by any previously identified c-Myc regulatory mechanism, does not require new protein synthesis, and does not depend on the nuclear localization of c-Myc. Degrasyn reduced c-Myc levels in A375 melanoma cells and in A375 tumors in nude mice, and this activity correlated with tumor growth inhibition. Together, these results suggest that degrasyn reduces the stability of c-Myc in vitro and in vivo through a unique signaling process that uses c-Myc domains not previously associated with c-Myc regulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440106     DOI: 10.1158/0008-5472.CAN-06-4464

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint.

Authors:  Key-Hwan Lim; Myoung-Hyun Song; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2016-01-13       Impact factor: 9.261

2.  FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity.

Authors:  Zhichao Mei; Dawei Zhang; Bo Hu; Jing Wang; Xian Shen; Wuhan Xiao
Journal:  J Biol Chem       Date:  2015-05-05       Impact factor: 5.157

Review 3.  Targeting the ubiquitin-proteasome system for cancer therapy.

Authors:  Min Shen; Sara Schmitt; Daniela Buac; Q Ping Dou
Journal:  Expert Opin Ther Targets       Date:  2013-07-04       Impact factor: 6.902

4.  Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.

Authors:  Lan V Pham; Archito T Tamayo; Changping Li; William Bornmann; Waldemar Priebe; Richard J Ford
Journal:  Mol Cancer Ther       Date:  2010-07-06       Impact factor: 6.261

5.  Deubiquitinating ALDH1A3 key to maintaining the culprit of aggressive brain cancer.

Authors:  Hiroaki Wakimoto
Journal:  J Clin Invest       Date:  2019-04-08       Impact factor: 14.808

6.  Francisella tularensis induces ubiquitin-dependent major histocompatibility complex class II degradation in activated macrophages.

Authors:  Justin E Wilson; Bhuvana Katkere; James R Drake
Journal:  Infect Immun       Date:  2009-08-24       Impact factor: 3.441

7.  Nickel compounds induce apoptosis in human bronchial epithelial Beas-2B cells by activation of c-Myc through ERK pathway.

Authors:  Qin Li; Ting-Chung Suen; Hong Sun; Adriana Arita; Max Costa
Journal:  Toxicol Appl Pharmacol       Date:  2008-12-16       Impact factor: 4.219

Review 8.  Targeting ubiquitination for cancer therapies.

Authors:  John Kenneth Morrow; Hui-Kuan Lin; Shao-Cong Sun; Shuxing Zhang
Journal:  Future Med Chem       Date:  2015-12-02       Impact factor: 3.808

9.  Infection by Toxoplasma gondii specifically induces host c-Myc and the genes this pivotal transcription factor regulates.

Authors:  Magdalena Franco; Anjali J Shastri; John C Boothroyd
Journal:  Eukaryot Cell       Date:  2014-02-14

10.  Mechanisms of c-myc degradation by nickel compounds and hypoxia.

Authors:  Qin Li; Thomas Kluz; Hong Sun; Max Costa
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.